Novo Holdings Closes Sale of KabaFusion

BOSTON, February 2, 2026 –Novo Holdings, a leading healthcare investment firm, announced today that the sale of KabaFusion to Nautic Partners has successfully closed.

Headquartered in Cerritos, CA, and Lexington, MA, KabaFusion was founded in 2010 by Chief Executive Officer Dr. Sohail Masood, a pioneer in patient-focused intravenous immunoglobulin (IVIG) infusion therapies with more than three decades of clinical experience. Today, KabaFusion is licensed to serve patients in 45 states through its expansive network of 33 infusion pharmacies and 21 ambulatory infusion suites.

Jonathan Levy, Senior Partner, Novo Holdings, said: “From its founding, KabaFusion has kept patients at the center of everything they do. This vision attracted Novo Holdings to partner with management to help bring convenient and cost-effective therapy to a broad array of patients. We are pleased with this successful exit and wish KabaFusion and Nautic continued success as they advance the company’s growth trajectory.”

Abhijeet Lele, Senior Partner, Novo Holdings, said: “KabaFusion exemplifies what strong, patient-centered healthcare platforms can achieve when clinical leadership, operational discipline, and mission alignment come together. We thank Dr. Sohail Masood and the KabaFusion team for a highly collaborative partnership and wish them continued success on their journey.”

Dr. Masood, CEO and founder, KabaFusion, said: “We have made significant achievements in delivering innovative infusion therapies and exceptional outcomes to patients and providers since partnering with Novo Holdings in November 2022. During that time, KabaFusion nearly doubled in size, greatly expanding our national presence. We are excited to work with Nautic as we launch our next chapter, confident our partnership can further accelerate our growth and aid us in continuing to set the standard for clinical excellence nationwide.”

Goodwin Procter LLP and Linklaters LLP served as legal counsel, Houlihan Lokey, Inc., served as financial advisor, and Epstein Becker & Green, PC, served as regulatory counsel to KabaFusion. Kirkland & Ellis LLP served as legal advisor to Nautic.

About Novo Holdings

Novo Holdings is a holding and investment company responsible for managing the assets and wealth of the Novo Nordisk Foundation. The purpose of Novo Holdings is to improve people’s health and the sustainability of society and the planet by generating attractive long-term returns on the assets of the Novo Nordisk Foundation. Wholly owned by the Foundation, Novo Holdings is the controlling shareholder of Novo Nordisk A/S and Novonesis A/S (formerly Novozymes A/S) and manages an investment portfolio with a long-term return perspective. In addition to managing a broad portfolio of equities, bonds, real estate, infrastructure, and private equity assets, Novo Holdings is a world-leading life sciences investor. Through its Seed, Venture, Growth, Asia, Planetary Health, and Principal Investments teams, Novo Holdings invests in life sciences companies at all stages of development. As of year-end 2024, Novo Holdings had total assets of USD 148 billion. www.novoholdings.dk.